STOCKHOLM, Jan. 27, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic's partner Eisai's Supplemental Biologics License Application (sBLA) for Leqembi as a once every four weeks...
Read More Details
Finally We wish PressBee provided you with enough information of ( FDA approves IV maintenance dosing of Leqembi® (lecanemab-irmb) for the treatment of early Alzheimer's Disease in the US )
Also on site :
- Bodies of two Israeli-American hostages recovered from Gaza in joint military operation
- Israel deports Greta Thunberg after intercepting Gaza-bound aid boat
- Diddy trial live: Ex-girlfriend ‘Jane’ describes what happened during sex parties after judge denies mistrial request